Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment
Beth L. Thurberg, George A. Diaz, Robin H. Lachmann, Thomas Schiano, Melissa P. Wasserstein, Allena J. Ji, Atef Zaher, M. Judith Peterschmitt
Dive into the research topics of 'Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment'. Together they form a unique fingerprint.